博瑞醫藥(688166.SH):公司及高管收到江蘇證監局警示函
格隆匯3月12日丨博瑞醫藥(688166.SH)公佈,公司於2020年3月12日收到中國證券監督管理委員會江蘇監管局於2020年3月11日印發的《江蘇證監局關於對博瑞生物醫藥(蘇州)股份有限公司及相關人員採取出具警示函監管措施的決定》。
公司於2020年2月12日披露《關於抗病毒藥物研製取得進展的公告》稱,“於近日成功仿製開發了瑞德西韋原料藥合成工藝技術和製劑技術。公司已經批量生產出瑞德西韋原料藥,瑞德西韋製劑批量化生產正在進行中”。經核查,公司公告中所稱“批量生產”實際為藥品研發中小試、中試等批次的試驗性生產,而非已完成審批並開始正式規模化、商業化生產銷售瑞德西韋原料藥和製劑。公司所披露的“批量生產”未考慮一般語義的理解,亦未作出專門説明,不能準確描述抗病毒藥物研製的進展,信息披露不準確。
上述行為違反了《上市公司信息披露管理辦法》第二條的規定。董事會祕書王徵野是公司信息披露的具體負責人,對此承擔主要責任。根據《上市公司信息披露管理辦法》第五十八條、五十九條的規定,江蘇監管局決定對公司及董事會祕書王徵野採取出具警示函的行政監管措施,並記入證券期貨市場誠信檔案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.